Document Detail

Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects.
MedLine Citation:
PMID:  24104417     Owner:  NLM     Status:  Publisher    
PURPOSE OF REVIEW: Warfarin has been the sole oral anticoagulant used in the management of thromboembolic disorders for over 60 years. Target-specific oral anticoagulants (TSOAs) have recently emerged as alternatives to warfarin, because they do not require laboratory monitoring. Nevertheless, with the rising use of TSOAs, there is growing concern among clinicians regarding management of bleeding in patients taking them. Unlike warfarin, there is no antidote or reversal agent for TSOAs. This review summarizes recent developments and attempts to provide a systematic approach to patients on TSOAs presenting with bleeding complications.
RECENT FINDINGS: Currently, data involving clinical management of TSOAs are limited and primarily based on ex-vivo or animal models using hemostatic agents with uncertain implications in bleeding patients. There is a pressing need for randomized clinical trials evaluating the safety and efficacy of hemostatic agents.
SUMMARY: Without evidence-based guidelines for TSOA management, appropriate patient care requires an understanding of TSOA pharmacology, their effect on coagulation tests and, hence, a correct interpretation of test results, as well as a systematic approach to bleeding complications.
Sean Yates; Ravi Sarode
Related Documents :
24084437 - Septic arthritis of the neonatal hip: acute management and late reconstruction.
1698507 - A direct cerebello-telencephalic projection in an electrosensory mormyrid fish.
25084627 - The management of osteoradionecrosis of the jaws - a review.
24381647 - Complete circumferential rectal ulceration and haemorrhage secondary to the use of a fa...
2665137 - The jewish contribution to medicine. part ii. the 19th and 20th centuries.
984177 - Identifying the potential rural optometrist.
Publication Detail:
Journal Detail:
Title:  Current opinion in hematology     Volume:  20     ISSN:  1531-7048     ISO Abbreviation:  Curr. Opin. Hematol.     Publication Date:  2013 Nov 
Date Detail:
Created Date:  2013-10-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9430802     Medline TA:  Curr Opin Hematol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  552-557     Citation Subset:  -    
Division of Transfusion Medicine and Hemostasis, Department of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pathogen inactivation: coming of age.
Next Document:  Geometric light trapping with a V-trap for efficient organic solar cells.